Cara touts sub­group in failed atopic der­mati­tis tri­al, but stock craters

Cara Ther­a­peu­tics will join the grow­ing list of biotech to launch a Phase III de­spite fail­ing Phase II.

The itch-fo­cused com­pa­ny an­nounced Thurs­day that its cen­tral drug, a pill called Ko­r­su­va, failed to sig­nif­i­cant­ly al­le­vi­ate itch­ing in pa­tients with atopic der­mati­tis when com­pared with place­bo. The drug missed both the pri­ma­ry end­point, the change in av­er­age score on a stan­dard itch scale af­ter 12 weeks, and the key sec­ondary end­point: The pro­por­tion of pa­tients who im­proved by at least 4 points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER